Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.
about
Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factorMechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsElucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulationsStable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnetCurrent perspectives on HIV-1 antiretroviral drug resistanceHIV-1 Reverse Transcriptase Structure with RNase H Inhibitor Dihydroxy Benzoyl Naphthyl Hydrazone Bound at a Novel SiteHIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanismHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateMechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variantsMechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP"Mixed inhibitors" of HIV-reverse transcriptase: synthesis and antiviral activityMode of inhibition of HIV reverse transcriptase by 2-hexaprenylhydroquinone, a novel general inhibitor of RNA-and DNA-directed DNA polymerasesThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors8-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcriptionMechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase.Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.Investigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations.Structures of complexes formed by HIV-1 reverse transcriptase at a termination site of DNA synthesis.Allosteric regulation of HIV-1 reverse transcriptase by ATP for nucleotide selection.Coordination between the polymerase and RNase H activity of HIV-1 reverse transcriptaseBiophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Nucleotide-dependent conformational change governs specificity and analog discrimination by HIV reverse transcriptase.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy?Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activityA cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection.The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC.Two proton transfers in the transition state for nucleotidyl transfer catalyzed by RNA- and DNA-dependent RNA and DNA polymerasesUnderstanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ during initiation and elongation of reverse transcription.Molecular matchmaking: NNRTIs can enhance the dimerization of HIV type 1 reverse transcriptase.Lys66 residue as a determinant of high mismatch extension and misinsertion rates of HIV-1 reverse transcriptase.
P2860
Q24548056-20E38746-0FF4-47C0-BCB6-1635A4BC8760Q24652511-5C591A65-C1D0-4AA2-8C52-F3EF8D91D1BFQ24654012-0F810399-8588-405C-93BF-CA4962E6749EQ24682670-1A83AC38-62CA-47F8-9E52-F3A2E685D633Q26852626-DFB32CB6-841A-4A49-AFD4-804474406184Q27640888-4FD82134-111F-4345-BB63-EE13B2623178Q27676835-60A09D53-B5C5-46E6-870E-225ACE753511Q28250395-B1C54C9C-99C6-42B8-AF35-16ABD705E908Q28343606-E6F1F829-B28E-4BF8-822F-BC3B1B3AA3C0Q28343830-62C42713-03D5-4CE6-A0EA-358AB0815C0BQ28370027-293C62F1-5E3B-4C1E-9FB0-E8577EA51D05Q28379011-674E9E1E-5C45-49CC-8718-5B5B73659A57Q28379139-A01D2C92-3878-459A-A3A8-2F7ABCE5CE5AQ28477840-5205F585-31BB-420D-B770-2EC1C5282100Q30318760-EC4E4CC4-2E1D-40CA-96A6-1F7AA28DB32EQ30409140-5C06765C-A017-406B-A1C9-9B050F1BECE2Q30456752-10FCCD24-6CB7-47E4-82A4-8190FC126D76Q30654060-7295B128-44DD-48F5-9BF8-F2AB359197D5Q33527409-5284C13C-89B6-41D0-B1B0-58A9872C7F9EQ33557531-44991656-6A10-452B-A76B-0AAD499F95FFQ33649797-036FAD1F-0EAD-4144-AABF-330DFC0420E4Q33842807-D5F50AEB-2EC6-4CC8-9A7A-92A4DF4FA4E6Q33896402-D10839DE-D21A-4C42-8E41-D3A4F2F7FD72Q33900459-E524B261-7D75-46CF-A2AF-93B049D39E55Q33972465-12DD1B00-723E-4EEC-B875-57E516BF8321Q33987492-923E48F2-FD23-4E13-A742-EE1449061281Q34163065-8E7B7045-FEF1-46C1-BF85-3AF241C5DB0FQ34242282-7423F9DA-3E6A-4082-B995-E807007789F9Q34352431-D8F35F16-61E6-4BA0-816D-899D6DE97503Q34669395-56B9725F-1EE7-40CE-A4D5-B6F154308804Q35105821-2DCE39D6-2888-4443-9D0C-80DEB86A2DBBQ35185934-42801492-45C2-404D-BE53-B581441CDBD3Q35659212-66504C44-9667-4665-B4DD-9BA661C040AFQ35684111-19162333-1FAB-490D-8A07-298808E1BD47Q35721277-E190F7B1-A341-4E74-B49B-13D7DD448F39Q35842525-5C60DF2B-F1DD-4BB3-9AF6-E646672893D1Q35917530-8036060D-0AD4-49C7-95E9-56E8AF343CB2Q35917913-7D8A949A-3CFA-4F3A-9BEA-5C98D0515C65Q36287526-494B3EC0-C2BB-4228-913C-A9D92FC0DF2EQ36319882-2C02A1E7-C2BC-4B67-B276-D6008BE29274
P2860
Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@ast
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@en
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@nl
type
label
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@ast
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@en
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@nl
prefLabel
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@ast
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@en
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@nl
P2093
P2860
P356
P1476
Human immunodeficiency virus r ...... n by nonnucleoside inhibitors.
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.17.8046
P407
P577
1995-08-01T00:00:00Z